Johnson & Johnson agree Ollin Biosciences deal

BY Richard Summerfield

Johnson & Johnson has agreed to acquire biotech company Ollin Biosciences in a deal worth up to $3.33bn, which will expand its pipeline of eye disease therapies.

Under the terms of the deal, Johnson & Johnson will pay $2.2bn upfront, with the potential for additional regulatory and commercial milestone payments taking the total to $3.33bn.

The deal is expected to close by the end of 2026, subject to applicable regulatory approvals and other customary closing conditions.

The deal will give Johnson & Johnson access to Ollin’s lead drug, OLN324, which is set to be studied in late-stage trials as a treatment for wet age-related macular degeneration and diabetic macular oedema, both of which can lead to severe vision impairment.

Johnson & Johnson will also enter into a separate agreement with Blackstone Life Sciences for a $750m multi-year funding for the late-stage development of OLN324, in ⁠exchange for ​some payments and royalties.

“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control,” said Kip Connor, vice president at Johnson & Johnson. “The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients.”

“Over the last three years, we’ve been on a mission to develop new therapies that improve the outcomes of patients with vision-threatening diseases,” said Jason S. Ehrlich, chief executive and co-founder of Ollin. “We’ve built a relentlessly execution-focused team and have rapidly advanced OLN324, generating compelling proof-of-concept data showing the potential for more effective improvements in retinal anatomy.

“We’re encouraged by what the future could hold and, subject to the completion of the transaction, the opportunity to build on our progress to date and further advance the development of OLN324 together,” he added.

“We founded Ollin with the conviction that pairing a world-class team with the capital necessary to acquire and smartly prosecute the development of next-generation therapeutics would allow us to challenge the status quo in ophthalmology,” said Paul Berns, managing director at ARCH Venture Partners, and co-founder and executive chairman of Ollin. “We’re confident that the potential acquisition of Ollin will enable OLN324 to reach as many patients as possible.”

Ollin, which has been backed by investment firms ARCH Venture ​Partners and Mubadala Capital, ​was established ⁠in 2023 to develop treatments for vision-threatening diseases. Its pipeline also includes OLN102, currently in preclinical development, for thyroid eye disease ​and Graves’ disease.

News: J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion

©2001-2026 Financier Worldwide Ltd. All rights reserved. Any statements expressed on this website are understood to be general opinions and should not be relied upon as legal, financial or any other form of professional advice. Opinions expressed do not necessarily represent the views of the authors’ current or previous employers, or clients. The publisher, authors and authors' firms are not responsible for any loss third parties may suffer in connection with information or materials presented on this website, or use of any such information or materials by any third parties.